Led · Series A · Mar 2026

Antiverse combines proprietary generative machine-learning models with programmable cell-line engineering to rapidly create epitope-specific, therapeutic-grade antibodies against difficult targets such as GPCRs and ion channels. Its lab-in-the-loop workflow reportedly reduces de novo antibody development timelines to under four months, integrating in-silico design with in-house build and validation. The company supports partnered discovery programs with several top-20 pharmaceutical firms and has just launched a research collaboration with the Cystic Fibrosis Foundation to generate antibodies targeting the extracellular region of CFTR. Backed by more than $20 million in total funding, Antiverse is expanding its platform, accelerating its internal pipeline, and intends to move its first wholly owned candidates into later-stage preclinical development by 2027. Headquartered in Cardiff, UK, with offices in Boston and Prague, the team has spent seven years training its models on challenging targets to optimize physicochemical properties and humanness of antibodies. Antiverse offers flexible collaboration structures to biotechnology, pharmaceutical, and foundation partners while simultaneously advancing its own therapeutics.

Led · Seed · Jan 2026

Founded in 2021, Geneva-based FluoSphera offers a 3D human-organ co-culture system that can house six to seven fluorescently coded tissue types in a single well, allowing researchers to evaluate drug efficacy and toxicity in one assay. The technology gives earlier, more human-relevant read-outs than traditional cell lines or animal studies and is already used by biotech and pharmaceutical partners, with strong traction in antibody-drug conjugate testing and a high-throughput screening collaboration with Revvity. FluoSphera claims its platform can save developers $100-500 million per molecule by cutting late-stage failures and time-to-market. The company aligns with regulatory shifts such as the FDA Modernisation Act 3.0 that encourage non-animal testing. Near-term plans include expanding commercial collaborations with pharma companies and CROs, bolstering business development, and enhancing AI-driven imaging analysis to scale the service. The firm also intends to extend its footprint across the US and EU while making initial inroads into Asia. Its recent CHF 1.15 million seed financing provides the capital to execute these growth initiatives.

Led · Seed · Oct 2025

London-based Rightcharge has developed a software platform that connects drivers’ home energy accounts, public charge cards and fleet vehicles into a single billing system, enabling automated, tax-compliant reimbursement for electric-vehicle charging. By crediting payments directly to electricity bills, the service maintains accuracy as tariffs change, reduces fraud through AI-driven anomaly detection, and produces HMRC-compliant audit trails. A companion public charge card gives access to more than 70 % of UK public chargers, while all costs flow into one consolidated monthly invoice. Early adopters include The Automobile Association (AA) and fleets across construction, healthcare and government sectors. Customers report up to 90 % reductions in charging costs, roughly 30 % lower carbon emissions and significantly reduced administrative work. The company plans to use new capital to expand across Europe, supported by a partnership with Octopus Electroverse. Rightcharge recently closed a seed funding round to finance these growth initiatives.

Led · Seed · Aug 2025

Better Medicine is a Tartu-based medical AI startup whose core product, BMVision Kidney, is an AI-powered tool that detects malignant lesions in CT scans to assist radiologists. BMVision Kidney became the first AI-based kidney cancer detection model to receive CE certification under the EU's Medical Device Regulation in early 2025. The company plans a European rollout of the CE-certified tool, preparation for FDA clearance, and FDA-aligned clinical pilots in the U.S. By automating lesion detection and measurement, Better Medicine says its software can reduce diagnostic delays, cut human error, and free radiologists to focus on complex clinical decision-making amid workforce shortages. The company highlights radiology strain — noting just 10 radiologists per 100,000 people in the UK and roughly half of open radiologist roles unfilled — and estimates 12 million hours annually are spent globally on manual lesion measurements and reporting. Financially, Better Medicine has raised more than €5 million to date (including €2.25M in private capital and €3.7M in grants, of which €2.5M was an European Innovation Council award) and has closed a €1M Pre-Seed round to fund rollout and U.S. pilots.

Led · Equity · Jun 2025

Lendorse offers upfront financing for international students’ tuition and living expenses through income share agreements (ISAs) and a suite of career-integration services. Its proprietary underwriting engine collects up to 150 data points and uses algorithms to predict future income distribution and assess creditworthiness for students from developing countries. Repayments begin only after graduates find professional success and are calculated as a fixed percentage of future income. The platform also provides CV assessments, mock interviews, mentorship, and relocation guidance to improve post-graduation outcomes. Lendorse intends to sharpen its underwriting capabilities, expand its lending partner network, and scale its team and product development. The company plans to deploy €10 million to fund over 1,000 students in the next 3–5 years. To date it has secured equity funding totalling €2.345 million, including a recent €1.75 million round and a €595K pre-seed. Lendorse is a Munich-headquartered social-impact fintech founded in 2022 that provides ‘Study Now, Pay Later’ education financing using Income Share Agreements (ISAs). The company finances tuition, relocation, and other study-related expenses for talented students from developing and emerging countries who lack collateral, credit history, or co-signers. Its model delays repayment until after graduation and ties payments to a percentage of future income once a threshold is exceeded. Lendorse has partnerships with blocked account provider Expatrio and universities including HSG St. Gallen, Stockholm School of Economics, and INSEAD. The European Investment Fund (EIF) supports Lendorse by securing defaults up to a certain amount, reducing Lendorse’s risk and enabling better student terms. With the newly secured capital, the company plans to expand its reach across Europe and scale its ISA program. The financing is intended to enable access to higher education in Europe for over 1,000 students.